in relation to that, look at todays aquisition of Auspex, wich went public in February 2014 at $12 per share, and today´s $101-per-share takeout is a huge and fast win for the company's shareholders. But Auspex has no approved products (its first drug will be filed later this year), so Teva is paying a big price for a company which does not have any product in the market!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.